Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

McKesson Inks Definitive Deal To Acquire Controlling Interest In Core Ventures For Approximately $2.49B In Cash, Which Will Represent ~70% Ownership

Author: Benzinga Newsdesk | August 26, 2024 08:03am

FCS physicians will continue to retain a minority interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). McKesson will purchase its controlling interest for approximately $2.49 billion in cash, which will represent approximately 70% ownership.

Following completion of the transaction, Core Ventures will be part of the Oncology platform, and financial results will be reported within McKesson's US Pharmaceutical segment.

Posted In: MCK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist